

# Faculty

## Chair:

### **Professor Patrick Mismetti**

University of Saint-Étienne  
Saint-Étienne, France

## Speakers:

### **Professor Patrick Mismetti**

University of Saint-Étienne  
Saint-Étienne, France

### **Professor Sylvia Haas**

Technical University Munich  
Munich, Germany

### **Dr Lorenzo Mantovani**

Federico II University of Naples  
Naples, Italy

### **Professor Martin Prins**

Maastricht University  
Maastricht, The Netherlands

## **Sponsored by Bayer Schering Pharma AG**

The marketing authorization for rivaroxaban may vary from country to country. In France, rivaroxaban is approved for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.



# Thrombosis Management... Innovation in Practice


**Rivaroxaban... preparing to set new standards**

Chaired by Patrick Mismetti

Thursday 25 March 2010, 08:30–10:00

Hermes Auditorium, Nice Acropolis, Nice, France

A Satellite Symposium sponsored by Bayer Schering Pharma AG  
at the 15th Congress of the European Association of Hospital Pharmacists  
Nice, France  
24–26 March 2010



# Chairman's Welcome

Dear Participants,

We are delighted to invite you to attend a Satellite Symposium at the Congress of the European Association of Hospital Pharmacists focusing on how the oral, direct Factor Xa inhibitor rivaroxaban has the potential to simplify and improve thrombosis management in clinical practice.

Venous thromboembolism (VTE) can be fatal, or have disabling, chronic and costly consequences for patients' health. It was recently estimated that there were over 760,000 cases of VTE per annum in just six European countries. Although anticoagulant therapy provides effective prophylaxis, classical agents such as low molecular weight heparins and vitamin K antagonists have drawbacks that limit their use.

The Satellite Symposium will cover a number of informative topics, and will open with a review of the pharmacological profile of rivaroxaban. Professor Sylvia Haas will present results from a pooled data analysis of three phase III studies (RECORD1–3) that compared rivaroxaban and enoxaparin regimens for the prevention of VTE after elective total hip or knee replacement surgery. Dr Lorenzo Mantovani will review the economic benefits of effective anticoagulation in VTE prevention. Finally, Professor Martin Prins will present the results of the phase III EINSTEIN Extension study, which compared rivaroxaban with placebo for the long-term secondary prevention of recurrent symptomatic VTE, and will conclude with an update on the rivaroxaban clinical trial programme.

We hope that you will be able to join us for what promises to be a very interesting and informative session.

Kind regards,

A handwritten signature in blue ink, appearing to read 'Patrick Mismetti', with a long, sweeping underline.

Patrick Mismetti

# Thrombosis Management... Innovation in Practice

## Rivaroxaban... preparing to set new standards

Chaired by Patrick Mismetti

**Thursday 25 March 2010, 08:30–10:00**

Hermes Auditorium, Nice Acropolis, Nice, France

A Satellite Symposium sponsored by Bayer Schering Pharma AG at the EAHP Annual Congress 2010, 24–26 March 2010

- |       |   |
|-------|---|
| 08:30 | <b>Welcome and introduction</b><br>Patrick Mismetti, France   |
| 08:35 | <b>Pharmacological profile of rivaroxaban</b><br>Patrick Mismetti, France   |
| 08:50 | <b>Rivaroxaban for the prevention of thromboembolic events after elective major orthopaedic surgery: RECORD1–3 pooled data</b><br>Sylvia Haas, Germany        |
| 09:05 | <b>Economic benefits of effective anticoagulation in VTE prevention</b><br>Lorenzo Mantovani, Italy   |
| 09:20 | <b>New approaches on the duration of secondary prevention of thromboembolic events: The EINSTEIN Extension study results</b><br>Martin Prins, The Netherlands |
| 09:35 | <b>Rivaroxaban: Clinical trial programme update</b><br>Martin Prins, The Netherlands  |
| 09:45 | <b>Panel and audience discussion</b><br>Patrick Mismetti, France  |
| 09:55 | <b>Closing remarks</b><br>Patrick Mismetti, France  |

